MSC Clinical Trials: What ISCT Dublin Revealed About Meniscal Repair, Mitochondrial Transfer, and Cell Sourcing

A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.

Читать далее...

Stem Cell Therapy for Spinal Cord Injury: What 2026 Research Tells Us About MSC Therapy After SCI

Japan approved the world’s first MSC therapy for spinal cord injury in 2018. Here’s what six years of real-world data and 2026 mechanism research tell us about where MSC therapy for SCI actually stands.

Читать далее...

Stem Cell Therapy for Erectile Dysfunction: A Patient’s Guide to the 2026 Evidence

Diabetic ED, post-prostatectomy ED, PDE5 non-responders — here’s what 2026 trials and clinical experience show for stem cell therapy: who is a candidate, what the procedure looks like, what it costs, and what to expect.

Читать далее...

MSC Therapy for Multiple Sclerosis: What 17 Trials and Tell Us

MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.

Читать далее...

MSC-Derived Exosomes for Myocardial Infarction: Delivery Systems, Mechanisms, and the Bench-to-Bedside Pipeline

Eight 2026 studies detail how MSC exosomes inhibit ferroptosis, deliver sustained paracrine signaling via hydrogels, and improve LVEF in rat MI models. Here is what translational researchers need to know before the first Phase 2 exosome trial reads out.

Читать далее...

Harnessing MSC-Derived Exosomes for Advanced Rheumatoid Arthritis Immunotherapy

Discover the groundbreaking potential of MSC-derived exosomes in revolutionizing Rheumatoid Arthritis immunotherapy. Learn about novel nanoplatforms and their mechanism of action.

Читать далее...

MSC Therapy for Diabetic Foot Ulcers: 2026 Mechanism, Hydrogel Delivery, and Real-World Trial Outcomes

2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputation in Thailand.

Читать далее...

Allogeneic vs Autologous Stem Cells: What 2026 Evidence Says Is Better

2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.

Читать далее...

Stem Cell Therapy for Osteoporosis: What 2026 Research Means for Women After Menopause

Osteoporosis after menopause affects millions of women. New 2026 research shows mesenchymal stem cells and exosomes can rebuild bone density safely. Here’s what patients need to know.

Читать далее...
Top